PharmacoEconomics & Outcomes News

, Volume 819, Issue 1, pp 20–20 | Cite as

Evaluating acalabrutinib in mantle cell lymphoma

Meeting report


  1. Alrawashdh N, et al. Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. 60th Annual Meeting and Exposition of the American Society of Hematology : abstr. 4829, 1 Dec 2018. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations